23:51 , May 21, 2019 |  BC Extra  |  Clinical News

May 21 Clinical Quick Takes: Array gains on colorectal cancer plans; plus Tocagen, Promedior

Array planning submissions for colorectal cancer triplet  Array BioPharma Inc. (NASDAQ:ARRY) gained $4.81 (23%) to $25.77 on Tuesday after interim data from the Phase III BEACON CRC trial to treat BRAF V600E-mutant metastatic colorectal cancer...
23:09 , May 10, 2019 |  BioCentury  |  Product Development

Exelixis to fuel pipeline growth with Cabometyx cash flows

On the back of the successful launch of Cabometyx cabozantinib, Exelixis is not only using the increased free cash flow to expand the drug’s label, it also thinks it has the firepower to build out...
21:58 , Apr 26, 2019 |  BioCentury  |  Product Development

Rise of the independents, biotechs go to market

While product launch and commercialization has largely been the province of big biotech and big pharma, with smaller companies partnering to get their products over the finish line, BioCentury’s analysis of recent FDA approvals finds...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
02:16 , Apr 5, 2019 |  BC Innovations  |  Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
10:30 , Apr 1, 2019 |  BC Extra  |  Financial News

SpringWorks raises $125M series B round

A year and a half after raising its initial round of funding to develop programs spun out of Pfizer, SpringWorks has raised $125 million in a series B round. The company now has funding to...
19:56 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

Guardant's liquid biopsy is faster, as effective as tissue biopsy

Guardant Health Inc. (NASDAQ:GH) said its Guardant360 liquid biopsy detected biomarkers at a similar rate as standard-of-care tissue genotyping tests, but faster. Data were presented at a media preview ahead of the American Association for...
05:34 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

Array reports updated Phase III OS data for triple combo mCRC therapy

Array BioPharma Inc. (NASDAQ:ARRY) reported updated data from the safety lead-in portion of the Phase III BEACON CRC trial showing that encorafenib (LGX818) plus binimetinib (MEK162) and Erbitux cetuximab led to a median overall survival...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
13:08 , Dec 4, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; tissue markers Analysis of the copy numbers of mutant and wild-type alleles of oncogenes could help predict response to cancer therapies targeting those oncogenes. The method involves: performing genome-wide, allele-specific copy number...